Anti-cyclic Citrullinated Peptide Antibodies Are a Collection of Anti-citrullinated Protein Antibodies and Contain Overlapping and Non-overlapping Reactivities
Overview
Authors
Affiliations
Objective: Anti-citrullinated protein antibodies (ACPA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of rheumatoid arthritis and are believed to play a role in disease pathogenesis. These antibodies are typically detected in ELISA with citrullinated peptides (eg, CCP2) or proteins as antigens. The absolute concentration of anti-CCP antibodies in serum is unknown. Although antibodies to several citrullinated proteins can mainly be detected within anti-CCP-positive sera, it is currently unknown whether anti-CCP antibodies are in fact ACPA. Likewise, it is unknown to what extent antibody responses to different citrullinated antigens are crossreactive.
Methods: An affinity purification method was established in which citrullinated antigen-specific antibodies were eluted from ELISA plates and then used for detection of other citrullinated antigens in ELISA or western blot. For additional crossreactivity studies, ELISA-based inhibition assays were performed with citrullinated or control peptides as inhibitors.
Results: The concentration of anti-CCP IgG antibodies was estimated to be at least 30 μg/ml in patients with high anti-CCP levels (>1600 μg/ml). Affinity-purified anti-CCP antibodies were able to recognise citrullinated fibrinogen (cit-fib) and citrullinated myelin basic protein (cit-MBP) on western blot. Furthermore, antibodies specific for cit-fib and cit-MBP were crossreactive. However, additional crossreactivity studies indicated that non-overlapping antibody responses to citrullinated peptides can also exist in patients.
Conclusions: This report shows for the first time that anti-CCP antibodies recognise multiple citrullinated proteins and are thus a collection of ACPA. More importantly, the data indicate that different ACPA responses are crossreactive, but that crossreactivity is not complete, as distinct non-crossreactive responses can also be detected in patients with RA.
Haro I, Castellanos-Moreira R, Sanmarti R, Gomara M Diagnostics (Basel). 2024; 14(22).
PMID: 39594151 PMC: 11593125. DOI: 10.3390/diagnostics14222485.
Stork E, van Rijswijck D, van Schie K, Hoek M, Kissel T, Scherer H Nat Commun. 2024; 15(1):3114.
PMID: 38600082 PMC: 11006680. DOI: 10.1038/s41467-024-47337-x.
Yeh F, Cherng J, Chang S, Huang W, Chen H Heliyon. 2023; 9(12):e22745.
PMID: 38089987 PMC: 10711136. DOI: 10.1016/j.heliyon.2023.e22745.
Batsalova T, Teneva I, Bardarov K, Moten D, Dzhambazov B Cent Eur J Immunol. 2023; 48(3):174-188.
PMID: 37901867 PMC: 10604640. DOI: 10.5114/ceji.2023.131455.
Scherer H, van der Woude D, Toes R Nat Rev Rheumatol. 2022; 18(7):371-383.
PMID: 35606567 DOI: 10.1038/s41584-022-00786-4.